[Outcome of chronic hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive drugs and anti-TNF agents]

Gastroenterol Hepatol. 2014 Jan;37(1):23-4. doi: 10.1016/j.gastrohep.2013.07.008. Epub 2013 Oct 2.

[Article in Spanish]

Authors

Cristina González-Artacho¹, María José Rodríguez Sicilia², Carlos Alegría-Motte², María Gómez García²

Affiliations

¹ Servicio de Aparato Digestivo, Hospital Universitario Virgen de las Nieves, Granada. Electronic address: crisglart@gmail.com.
² Servicio de Aparato Digestivo, Hospital Universitario Virgen de las Nieves, Granada.

PMID: 24094622
DOI: 10.1016/j.gastrohep.2013.07.008

No abstract available

Publication types

Letter

MeSH terms

Adalimumab
Adenine / analogs & derivatives*
Adenine / therapeutic use
Adult
Antibodies, Monoclonal, Humanized / therapeutic use
Antiviral Agents / therapeutic use*
Azathioprine / therapeutic use
Crohn Disease / complications
Crohn Disease / drug therapy*
Female
Hepatitis B, Chronic / complications*
Hepatitis B, Chronic / drug therapy
Hepatitis C, Chronic / complications*
Hepatitis C, Chronic / drug therapy
Humans
Immunosuppressive Agents / adverse effects*
Immunosuppressive Agents / therapeutic use
Lamivudine / therapeutic use*
Male
Organophosphonates / therapeutic use*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Viral Load
Viremia / complications
Viremia / drug therapy
Viremia / prevention & control*
Virus Activation

Substances

Antibodies, Monoclonal, Humanized
Antiviral Agents
Immunosuppressive Agents
Organophosphonates
Tumor Necrosis Factor-alpha
Lamivudine
adefovir
Adalimumab
Adenine
Azathioprine